Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PAX8 and MECOM are interaction partners driving ovarian cancer.

Autor: Bleu M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Mermet-Meillon F; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Apfel V; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Barys L; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Holzer L; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Bachmann Salvy M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Lopes R; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Amorim Monteiro Barbosa I; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Delmas C; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Hinniger A; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Chau S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Kaufmann M; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Haenni S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Berneiser K; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.; Biozentrum, University of Basel, Basel, Switzerland., Wahle M; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Moravec I; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Vissières A; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Poetsch T; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Ahrné E; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Carte N; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Voshol J; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland., Bechter E; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Hamon J; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Meyerhofer M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Erdmann D; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Fischer M; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Stachyra T; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Freuler F; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Gutmann S; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Fernández C; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Schmelzle T; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Naumann U; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Roma G; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Lawrenson K; Cedars-Sinai Women's Cancer Program at the Samuel Oschin Cancer Center, Los Angeles, CA, USA., Nieto-Oberhuber C; Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland., Cobos-Correa A; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland., Ferretti S; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland., Schübeler D; Friedrich Miescher Institute for Biomedical Research, University of Basel, Basel, Switzerland.; Faculty of Science, University of Basel, Basel, Switzerland., Galli GG; Disease area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland. giorgio.galli@novartis.com.

Publikováno v: Nature communications [Nat Commun] 2021 Apr 26; Vol. 12 (1), pp. 2442. Date of Electronic Publication: 2021 Apr 26.

Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli.

Autor: Zhou X; Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266042, China., Zhang J; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, PR China., Chen J; Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266042, China.; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, PR China., Wang L; Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266042, China.; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, PR China., Yu M; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, PR China., Sy SKB; Department of Statistics, State University of Maringá, Maringá, Paraná, Brazil. sherwin.kenneth.sy@gmail.com., Yang H; Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266042, China. yanghqd79@163.com.

Publikováno v: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2024 Jul; Vol. 43 (7), pp. 1393-1405. Date of Electronic Publication: 2024 May 09.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Autor: Vaupel A; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. Electronic address: andrea.vaupel@novartis.com., Holzer P; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Ferretti S; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Guagnano V; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Kallen J; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Mah R; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Masuya K; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Ruetz S; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Rynn C; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Schlapbach A; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Stachyra T; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Stutz S; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Todorov M; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Jeay S; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland., Furet P; Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 Nov 01; Vol. 28 (20), pp. 3404-3408. Date of Electronic Publication: 2018 Aug 26.